Treatment of tumor-bearing mice with a-CTLA4-TGFβRII was significantly more effective at inhibiting tumor progression (p < 0.02, Student’s unpaired t-test) (Fig. 4d), reducing FOXP3+ expressing Tregs (p < 0.001, Student’s unpaired t-test) (Fig. 4e, left) and elevating tumor reactive IFNγ-expressing CD8+ cells (p < 0.01, Student’s unpaired t-test) (Fig. 4e, right) compared with the a-CTLA-4 alone, IgG-TGFβRII alone, and even the combination of a-CTLA-4 and nonspecific IgG-TGFβRII (Fig. 4d, e). This evidence concerns the gene CTLA4 and neoplasm.